Dr. Louis Aledort
MD
Biography
Dr. Aledort is a chaired Professor of Medicine at the Mount Sinai School of Medicine. He was educated and trained at Albert Einstein College of Medicine, Universities of Rochester and Virginia, and spent two years at the National Institute of Health. He has spent his career in the area of bleeding disorders.
He has served as consultant to the World Health Organization, Pan American Health Organization, House Ways & Means Committee. He has chaired and/or been a member of the practice committees of the American Society of Hematology and American College of Physicians.
He has written more than 400 articles on several aspects of bleeding and clotting disorders. Emphasis has been on the supply availability and affordability of blood products. He has been involved in developing health care programs and their underwriting in developing nations. Dr. Aledort has consulted for CSL Behring, American Red Cross, and Baxter BioScience.
He has received the Lifetime Achievement Awards from the Hemostasis and Thrombosis Research Society and from the Albert Einstein College of Medicine.
Key Publications
-
Aledort LM. Off-Label Use of Recombinant Activated Factor VII -Safe or Not Safe? N Engl J Med 2010; 363: 19: 1853-1854.
-
Aledort LM. Another role for the VW molecule. Haemophilia 2012; 18: 246-247.
-
Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-2192.
Key Institutions
-
Mount Sinai School of Medicine
New York, USA
Current Positions/Chairs
-
Chair
The Mary Weinfeld Professor of Clinical Research in Hemophilia at Mount Sinai School of Medicine -
Co-Chair
International Prophylaxis Study Group (IPSG)
Research Interests
-
Bleeding and clotting disorders
-
Clinical trials
-
Healthcare economics
Publications
Challenges associated with access to recently developed hemophilia treatments in routine care – healthcare professionals’ perspectives.
Authors
Berger K, O’Rourke RH, Matteo Nicola DD, Batorova A, Kavakli K, Mannuccio PM, Wolfgang Schramm W, Rhonda BL, Aledort L on behalf of the International Prophylaxis Study Group.
Citation
Hematologica. 2024 Mar 1; 110(3):673-682. DOI: 10.3324/haematol.2024.285647
Are all licensed hemostatic agents for hemophilia therapy accessible to patients? Letter to the Editor
Authors
Berger K, Batorova A, Bohn RL, di Minno M, Mannucci P, Kavakli K, Schramm W, Aledort L on behalf of the International Prophylaxis Study Group
Citation
Haemophilia. 2022; 28:e256–e258. DOI: 10.1111/hae.14660
Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis
Authors
Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).
Citation
Haemophilia. E-Pub July 10, 2018
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia
Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia
Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5):e447 - e450
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors).
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators
Citation
57th American Society of Hematology Meeting 2015.
Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)
Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.
Authors
Aledort L, Avila ML, Blanchette V, Lambert T and On behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.
Citation
Journal of Thrombosis and Haemostasis 2015, 13 (S2), # OR105, 134
Prophylaxis practices in children and adults with inhibitors.
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation
Journal of Thrombosis and Haemostasis 2015, 13 (S2), # PO270-MON, 360.
Tertiary prophylaxis in adults: What is the rationale?
Authors
Gringeri A, Lambert T, Street A, and Aledort L. on behalf of the Adolescent/Adult Prophylaxis Study Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012 Sept; 18 (5): 722-728
Tertiary prophylaxis in adults: What is the rationale?
Authors
Gringeri A, Lambert T, Street A, and Aledort L. on behalf of the Adolescent/Adult Prophylaxis Study Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012 Sept; 18 (5): 722-728
Why should we Care about Quality of Life in Hemophilia?
Authors
Aledort L, Bullinger M, von Mackensen S, Wasserman J, and Young NL. on behalf of the Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group.
Citation
Haemophilia 2012; May 18 (3) : e154 – e157.
The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.
Authors
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.
Citation
Haemophilia 2007 Nov; 13 (6): 745-749.
Are randomized clinical trials the only truth? Not always
Authors
Aledort L, Ljung R, and Blanchette V on behalf of the International Prophylaxis Study Group (IPSG)
Citation
Journal of Thrombosis and Haemostasis 2006 Mar; 4 (3): 503 - 504.